Sellas Life Sciences Group shares rise 7% ahead of leukemia clinical trial results
SLS SELLAS Life Sciences Group Inc
$7.86 -2.12%
View chart & analysis → - 1Sellas Life Sciences Group Inc announced that results from a much-anticipated leukemia clinical trial are expected later this month.
- 2The CEO emphasized that if the results are successful, the treatment has the potential to be a transformative immunotherapy.
- 3The trading price of $8.59 for SLS rebounded after a 46% decline from its all-time high on June 30.
So what's the key point?
Sellas Life Sciences Group will announce results from a leukemia treatment trial at the end of this month. The stock rose to $8.59 because the results could lead to a new type of treatment.
Source Schaeffer's Research · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.